Compare ETSY & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETSY | SRRK |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.6B |
| IPO Year | 2015 | 2018 |
| Metric | ETSY | SRRK |
|---|---|---|
| Price | $62.30 | $41.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 28 | 9 |
| Target Price | ★ $62.60 | $47.88 |
| AVG Volume (30 Days) | ★ 3.1M | 1.1M |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | ★ $2,854,027,000.00 | N/A |
| Revenue This Year | $4.80 | N/A |
| Revenue Next Year | $2.99 | $20,271.77 |
| P/E Ratio | $33.28 | ★ N/A |
| Revenue Growth | ★ 1.98 | N/A |
| 52 Week Low | $40.05 | $22.71 |
| 52 Week High | $76.52 | $48.28 |
| Indicator | ETSY | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 69.15 | 46.68 |
| Support Level | $55.01 | $41.19 |
| Resistance Level | $56.78 | $46.14 |
| Average True Range (ATR) | 1.93 | 1.75 |
| MACD | 1.02 | -0.76 |
| Stochastic Oscillator | 86.71 | 12.54 |
Etsy operates a top-10 e-commerce marketplace in the US and the UK, with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $12.5 billion in 2024 consolidated gross merchandise volume, Etsy has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. The firm connects about 95 million buyers and 8 million sellers on its marketplace properties: Etsy and Depop (clothing resale).
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.